Baxter International Inc. in the news

Baxter International, a healthcare company, provides medical products and technologies like surgical products, drug compounding, and connected-care platforms to hospitals and clinicians globally.

Baxter International Inc. stock performed better than competitors, despite daily losses.

Barclays initiated coverage on Baxter International with an Underweight rating and a $20 price target, and the document details various financial and ESG rating methodologies.

Baxter International Inc. will hold a conference call on October 29, 2026, to discuss its third-quarter 2026 financial results.

Evercore ISI has raised its price target for Baxter International from $24 to $32, based on various weighted average ratings.

Baxter International (BAX) stock has significantly outperformed its Medical sector peers year-to-date with a 26.7% return, driven by improving earnings estimates and positive analyst sentiment.

Baxter International appears to be undervalued based on its strong Zacks Rank, Value grade, and favorable P/E, PEG, P/B, and P/S ratios compared to industry averages.

Baxter International Inc. shares experienced a 3.11% increase to $24.22 on Monday, outperforming competitors and ending a two-day losing streak.

Citigroup trimmed Baxter International's price target to $27 from $28 while keeping a Neutral rating.

Zacks Research lowered Baxter International's third-quarter 2026 earnings estimate despite strong Q2 results and maintained full-year guidance, leading to a 1.49% stock gain.

Baxter International Inc. released its 2026 Connected Hospital Report, analyzing how U.S. hospitals leverage technology, revealing maturity levels, and identifying key priorities and challenges.

Baxter International Inc. stock is undervalued by 23.6% at $24.22, despite profitability and cash flow concerns.

Baxter International's stock dipped slightly after-hours, while the company released a report on hospital technology maturity based on a survey of IT and nursing leaders.

Baxter International Inc. provides a portfolio of essential healthcare products across various segments including medical products, healthcare systems, and pharmaceuticals.

Baxter International Inc. stock saw a 2.21% increase to $24.00 on Wednesday, outperforming the S&P 500 and Dow Jones Industrial Average.

Baxter International Inc. faces investor scrutiny on whether its hospital and kidney-care products can deliver consistent execution to offset financial pressures.

Baxter International's stock performance is mixed, but its recent report on hospital technology use and long-term growth drivers suggest undervaluation, though risks remain.

Baxter International's Q3 2026 EPS estimate has been cut to USD 0.51, despite exceeding Q2 revenue and EPS forecasts.

Baxter International's stock is trading above analyst targets following a Q2 revenue increase and raised 2026 guidance, despite declining margins.

Baxter is transforming its portfolio, focusing on operational efficiency, connected care growth, and strengthening higher-growth businesses while navigating challenges from manufacturing costs and regulatory issues.